Porto

• Bioequivalence of Etonogestrel 68 mg Implant in Healthy Pre-Menopausal, Non-Pregnant Female Participants. Ended
  2025-520736-41-00 2 2025-06-17 No medical condition
• Bioequivalence of One Tablet of Gliclazide MR 90 mg (S005190) and One and a Half Tablets of Gliclazide MR 60 mg (Diamicron® MR) in Healthy P … Ended
  2024-519567-18-00 2 2025-06-02 No medical condition.
• Bioequivalence of One Tablet of Gliclazide MR 120 mg (S005190) and Two Tablets of Gliclazide MR 60 mg (Diamicron® MR) in Healthy Participant … Ended
  2024-519470-39-00 2 2025-05-30 No medical condition.
• Investigate Drug-Drug Interactions between LVDS (Levonorgestrel Vaginal Delivery System) and Tampons and Lubricants in Healthy Female Partic … Ended
  2025-520517-32-00 3 2025-05-29 No medical condition.
• Investigation of Drug-Drug Interactions between LVDS (Levonorgestrel Vaginal Delivery System) and Miconazole in Healthy Female Participants. Ended
  2025-520516-33-00 3 2025-05-28 No medical condition.
• Bioequivalence of One Tablet of Gliclazide MR 120 mg (S005190) and Two Tablets of Gliclazide MR 60 mg (Diamicron® MR) in Healthy Participant … Ended
  2024-519250-37-00 2 2025-05-27 No medical condition.
• Multiple-Dose Study on the Bioequivalence of One Tablet of Gliclazide MR 120 mg (S005190) and Two Tablets of Gliclazide MR 60 mg (Diaprel® M … Ended
  2024-519640-32-00 2 2025-04-22 No medical condicion.
• Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® … Ended
  2023-507865-24-00 5 2025-03-28 Advanced (unresectable/metastatic) melanoma
• Evaluation of the Effect of Itraconazole, Quinidine and Rifampicin on the Single-Dose Pharmacokinetics of ZED1227 Ended
  2024-518734-87-00 3 2025-03-25 No medical condition.
• Bioequivalence of Ruxolitinib 25 mg Tablets in Healthy Participants Under Fasting Conditions Ended
  2025-520716-34-00 2 2025-03-17 No medical condition.
• Bioequivalence of Lisdexamfetamine dimesylate 70 mg Capsules in Healthy Participants Under Fasting Conditions. Ended
  2024-516826-79-00 2 2025-03-10 No medical condition.
• Bioequivalence of Lisdexamfetamine dimesylate 20 mg Capsules in Healthy Participants Under Fasting Conditions. Ended
  2024-516827-14-00 2 2025-03-10 No medical condition.
• Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated Ended
  2024-512505-66-00 10 2025-03-03 HIV-1 Infection
• Drug-Drug Interaction between Empagliflozin 25 mg Film-Coated Tablets and Alogliptin 25 mg Film-Coated Tablets in Healthy Participants Under … Ended
  2025-520459-10-00 3 2025-02-18 No medical condition.
• Drug-Drug Interaction between Alogliptin 25 mg Film-Coated Tablets and Empagliflozin 25 mg Film-Coated Tablets in Healthy Participants Under … Ended
  2025-520460-18-00 3 2025-02-18 No medical condition.
• Bioequivalence of Calcifediol monohydrate 0.266 mg Soft Capsules in Healthy Participants Under Fasting Conditions. Ended
  2024-513480-37-00 2 2025-01-28 No medical condition.
• Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study of Efficacy and Safety of ESK-001 for Moderate to Severe Pl … Ended
  2023-507193-40-00 5 2025-01-16 Moderate to Severe Plaque Psoriasis
• Bioequivalence of Metamizole Sodium 500 mg Film-Coated Tablets in Healthy Participants Under Fasting Conditions. Ended
  2024-514447-29-00 2 2024-12-02 No medical condition.
• A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome Ended
  2023-507680-19-00 4 2024-11-28 Sjögren’s Syndrome
• Bioequivalence of Lisdexamfetamine dimesylate 10 mg/mL Oral Solution in Healthy Participants Under Fasting Conditions. Ended
  2024-516828-33-00 2 2024-11-15 No medical condition.
• Single-Ascending Doses of 2-Methoxyestradiol in Healthy Non-Pregnant Female Subjects. Ended
  2024-516854-23-00 1 2024-11-11 No medical condition.
• Bioequivalence of Ruxolitinib 20 mg Tablets in Healthy Participants Under Fasting Conditions. Ended
  2024-515947-49-00 2 2024-10-07 No medical condition.
• A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe … Ended
  2024-511360-87-00 5 2024-10-02 hidradenitis suppurativa (HS)
• Bioequivalence of Linagliptin 5 mg Film-Coated Tablets in Healthy Participants Under Fasting Conditions Ended
  2024-516400-42-00 2 2024-10-02 No medical condition.

Showing 409–432 of 548 trials